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terology, Emory University School ofAn increasing number of patients with childhood liver disease survive into adulthood. These
young adults are now entering adult services and require ongoing management. Aetiologies
can be divided into liver diseases that develop in young adults which present to adult hepa-
tologists i.e., biliary atresia and Alagille syndrome or liver diseases that occur in children/ado-
lescents and adults i.e., autoimmune hepatitis or Wilson’s disease. To successfully manage
these young adults, a dynamic and responsive transition service is essential. In this review,
we aim to describe the successful components of a transition service highlighting the impor-
tance of self-management support and a multi-disciplinary approach. We will also review
some of the liver specific aetiologies which are unique to young adults, offering an update
on pathogenesis, management and outcomes.
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The number of patients with
childhood liver diseases sur-
viving into adulthood is
increasing. Adult hepatolo-
gists need to be familiar
with the management of
these diseases.
Key point
A sensitive and responsive
transition service is required
to manage young adults
with liver disease.
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(D. Joshi).The number of patients with childhood liver dis-
eases surviving into adulthood has increased over
the last 20 years. Diseases once thought to be only
in the domain of paediatric hepatologists are
increasingly seen in adult clinics. Greater aware-
ness and expertise is therefore required amongst
adult hepatologists to manage this unique cohort
and their disease spectrum. In addition, one of the
key barriers for a successful transition from paedi-
atric to adult care is an inexperience or a lack of
knowledge in treating childhood diseases [1,2].
One of the important developments in health
care services for young adults is the setup of sensi-
tive and responsive transition services. Transition
services across all disciplines in medicine play an
important role in ensuring the health of young
adults is maintained through a holistic approach
and supportive environment. The importance of
transition services cannot be understated. Even
without ill health, young adults (18–24 years old)
are a high-risk cohort with higher mortality rates
compared to 12–17 year olds and higher rates of
substance misuse and suicide [3]. Add in the pres-
ence of a chronic illness that goes hand in hand
with the necessity of regular medication intake
and the situation becomes even more precarious.
Developmentally appropriate care for young adults
remains key.Journal of HepatoThis article will highlight the important compo-
nents of a successful transition service, the multi-
disciplinary approach and the successful outcomes
that are possible. We will also review the liver aeti-
ologies that develop in young children but will pre-
sent to adult hepatologists as well as the aetiologies
that occur in children/adolescents and adults con-
centrating on the practical management of these
patient cohorts.Aims of transition care
There is a need to emphasise that the terms ‘transi-
tion’ and ‘transfer’ are not synonymous. Transfer
only refers to the change in location where care will
be delivered, change in health care provider or both
[4,5]. Therefore, transfer, is but a component of tran-
sition. Transition, on the other hand is not a single
event but a purposeful, planned process of moving
adolescents and young adults with chronic medical
and physical conditions from a child centre to an
adult-orientated health care system [5,6]. It is an
important milestone for patients, families, carers,
and paediatric and adult services as well as poten-
tially representing a period of vulnerability for the
individual patient.logy 2017 vol. 66 j 631–644
Key point
Self-management support is
an important strategy which
empowers young adults to
participate in their care.
Key point
Transition services need to
be holistic and adopt a
multi-disciplinary approach.
Successful transition services
aim to improve adherence
and long-term outcomes
R
e
v
ie
w
Review
632Timing of transition
During the transition process, the responsibility of
health care moves from the parent or carer to the
patient ideally at a pace which is suitable for all.
The first stage of transition in the shared manage-
ment model begins approximately at 10 years of
age and involves the introduction of the concept
of transition [7,8]. Over the following years, a slow
process ensues of engaging and preparing these
young children in becoming independent young
adults [7,9]. The patient essentially swaps roles
with the parent or carer and takes on a more active
role in self-care activities (Fig. 1) [9], whilst
remaining the primary focus of attention. These
self-care activities include taking medications,
leading a healthy lifestyle and attending clinics on
their own. Moreover, the process needs to be indi-
vidualised according to physical, developmental,
educational, emotional and psychosocial needs of
the patient. Although most transition services will
typically specify an age range, i.e., 14–18 years, in
which patients move to an adult clinic, services
need a degree of flexibility, and physicians and
health care services may need to adapt to the needs
of the individual [10]. Older adolescents and young
adults for instance demonstrate higher rates of
non-adherence compared to younger children
[9,11]. Age alone should not be the single factor
which determines readiness of transfer to adult ser-
vices. Transfer of patient care to adult services
should only be during a period of clinical stability.
Outpatient services are more flexible with regards
to age but this is not usually the case for inpatient
care. The availability of a young adult ward is
therefore an ideal solution.
One should also acknowledge the challenges
faced by both the paediatric and adult teams. There
can be reluctance by the paediatric team in ‘letting
the patient go’, which can then have a detrimental
effect on the patient. On the other hand, busy adult
clinics, resulting in less time devoted to the young
adult and their families can make the adult team
appear uncaring and uninterested. Dedicated tran-
sition clinics are therefore vital [12].Self-management
Patients require more than just information and
therefore, the development of self-management
skills are integral to the successful transition of
patients [13]. Self-management support encour-
ages the individual to actively participate in the
care of their everyday symptoms relating to their
medical treatments in addition to maintaining their
general health and preventing progression of their
medical conditions [14,15]. Table 1 lists the most
important self-management skills an individual
should acquire prior to transitioning to adult ser-
vices. These self-management skills are developedJournal of Hepatology 2017 vol. 66 j 6by encouraging the patient to talk and answer ques-
tions. Initially this can be with their parent(s) pre-
sent and then eventually on an individual basis.
Other strategies may involve asking the patient to
prepare 2–3 verbal sentences in advance of the
clinic covering the topics of diagnosis, relevant past
medical history and medication. This strategy
encourages the young adult to develop self-
advocacy skills and engage directly with the health
care team. Another strategy is the creation of a
health care passport, made in combination with
the young adult, parent(s) and health care team. A
health passport lists the individual’s medical his-
tory, past procedures, medications, allergies and
other health related information. It also highlights
any disabilities and specific health care difficulties
i.e., being examined, having blood tests, tolerating
imaging. These health care passports further
empower the young adult and is also an important
educational opportunity.
Transition of patients with cognitive delay may
pose further difficulties. Identifying cognitive delay
should not be limited to IQ testing alone and should
encompass adaptive behaviour assessment (i.e.,
communication and social skills) [16]. Assessment
of capacity and the ability to decide upon treatment
options needs to be made in conjunction with par-
ents, carers and guardians. We recommend early
engagement with parents, and community based
services and clear communication between adult
and paediatric services.Transition team members and key objectives
Three major categories appear to be integral to
every transition service: 1) building and supporting
self-management; 2) engagement with the receiving
team; and 3) guidance of patients and families [17].
Yet, there is no single accepted model for transition
or the constituents of a transition team [18]. A nurse
coordinator (transplant and non-transplant), dedi-
cated paediatric and adult hepatologists, specialist
social workers and a clinical psychologist are all
integral members of a transition team. A multi-
disciplinary approach is imperative. Members of
the extended transition team include youth volun-
teers and patient mentors who are able to provide
a unique insight.The importance of transition services
Much of the literature in this regard is derived from
transplantation services. Studies performed in ado-
lescent transplant recipients provide information
which is transferable to adolescents with chronic
liver disease. Current data suggests that up to one-
third of adolescents are non-adherent with medica-
tion and their clinic visits, leading to worsening liver31–644
Time
Paediatric Adult
Pre-transition
12-16 years
Parent/guardian > pre-teen
16 years
Transition
16-25 years
Parent/Guardian = Adolescent
Young adult > parent/guardian
Young adult
18-30 years
Fig. 1. The transition process.
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function and possible organ failure [7,9,19,20]. The
prevalence of non-adherence in adolescent trans-
plant recipients can be as high as 50% [20]. One
must remember, that some degree of non-
adherence is part of normal adolescence behaviour
[21]. Transition services therefore, have to mini-
mize this risk taking behaviour and its conse-
quences. Barriers to successful transition include
inexperience or a lack of knowledge in managing
paediatric liver diseases and uncertainty in the
management of sexual and substance abuse issues
[1].
Non-adherence with medications, especially
immunosuppressants, is associated with an
increased incidence of graft failure and mortality
[22]. In addition, non-adherence to immunosup-
pression medication appears to be more prevalent
during transfer and was identified as a significant
cause of graft loss in 16% of paediatric liver trans-
plant recipients and 14% of paediatric renal trans-
plant recipients, respectively [23–27]. In stark
contrast, recent data from a single UK centre study
demonstrated comparable graft survival following
liver transplantation between a transition group
and two cohorts of young adults [28]. In the same
study, the most common indication for re-
transplantation was disease recurrence as opposed
to non-adherence, leading to chronic rejection. It is
therefore clear that future studies are required to
determine the long-term effects of a transition ser-
vice on patient and graft survival and adherence to
medications.
Reasons for non-adherence with medication are
multifactorial but can be divided into five broad
categories: socioeconomic factors, patient derived
factors, disease related factors, treatment related
factors and health care system/health care team
factors (Table 2) [29]. Key risk factors include lower
socioeconomic status, passive parent involvement,
side-effects related to medications and poor com-
munication with health care teams [27,30–34].Table 1. Checklist of self-management skills that should be
reviewed by the adult hepatology team during transition.
Health promotion. The individual:
 is able to contact his/her health care team
 knows when and how to access emergency
health care services (including mental
health services)
 can create and use a portable medical
history
 is able to make and attend clinic
appointments
 is able to maintain a health care record i.e.,
copies of clinic letters
 is able to communicate with health care
providers independent of parents/carers
Medications. The individual:
 is able to describe his/her medications,
indications and prescribed regimens
 is able to request repeat prescriptions
JournalThe majority of studies appear to focus on the
paediatric perspective. A recent study attempted to
delineate the adult perspective thereby hoping to
provide new insights and identifying unidentified
barriers to care [2]. Using a web-based survey of
USA adult hepatologists, respondents reported less
than 50% of transition patients had an adequate
knowledge of their condition and parent/guardian
present at the time of their first review in the adult
service. One-third reported having no transition
strategy and only 15% had a formal transition pro-
gramme. Poor adherence to medications and limited
knowledge of their condition coupled with poor
self-management of their condition were identified
as barriers to successful engagement of transition
patients [2]. Success is achievable. An integrated
transition clinic with an emphasis on improving
young adult’s health care experience through a
young adult clinic, improved patient adherence to
medication and engagement with health care provi-
ders resulting in reduced renal transplant failure
rates [35].
General advice:
- Sexually active young adults. Young adults may
be sexually active and therefore appropriate sex-
ual education and contraceptive advice is often
required. Immunosuppression i.e., mycopheno-
late mofetil and sirolimus may therefore need
to be changed due to the associated teratogenic-
ity in male and female patients [36]. Single hor-
mone progesterone is recommended which can
include a depot shot or daily pills. Intrauterine
devices appear to be safe. In the event of a suc-
cessful pregnancy, a gastroscopy is recom-
mended between the 20–24th week of
gestation in patients with cirrhosis or portal
hypertension to screen for varices [37].of Hepatology 2017 vol. 66 j 631–644 633
Table 2. Risk factors for non-adherence and approach. Modified from Dobbels et al. [20].
Risk factor Approach
Socioeconomic factors Social isolation
Family instability
Poor parental support
Single parent families
Cost of medication or clinic visits
Social worker review
Review eligibility for financial
support.
Patient derived factors Poor understanding of condition
Mental illness
Previous non-adherence
Past history of child abuse
Low self-esteem
Post-traumatic stress disorder
Patient passports
Clinical psychology review
Disease related factors Duration of illness
Lack of symptoms
Substance misuse
Review of clinical status
Peer support groups
Treatment related factors Side effects
Number of medications
Cost of medication
Regular review of medications
Health care system/health care team
factors
Poor communication between the different health care teams, patient and
parents
Poor relationship between health care teams, patient and parents
Lack of continuity of care
Clinic attendance resulting in time off school or work
Weekly multi-disciplinary
meetings
Identification of key care providers
Evening clinics
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634Non-teratogenic medications i.e., azathioprine
and ursodeoxycholic acid (UDCA) can be contin-
ued in pregnancy and whilst breast feeding.
- Risk taking behaviour. Young adults with
chronic liver disease and those who have under-
gone liver transplantation are just as likely to
exhibit similar risk taking behaviours as the
general population [38]. Further information
and education is therefore required regarding
smoking, the use of illicit drugs and alcohol.
Binge drinking is a key issue and problematic
pattern of alcohol use in young adults [39].
These issues need to be addressed while in pae-
diatric care, early in the process of transition.
- Bone health. Some young adults will require
long-term corticosteroids. We recommend an
assessment of bone densitometry every 3–
5 years. Vitamin D levels should also be assessed
and treated accordingly.
- Side effects of medications. The requirement
for long-term immunosuppressive agents can
lead to the development of renal impairment,
hypertension and diabetes. A yearly review for
the development of these complications is
recommended. Patients taking long-term aza-
thioprine are recommended to apply sun protec-
tion to exposed areas.Liver diseases that develop in young children
which will present to adult hepatologists
Biliary atresia
Biliary atresia (BA) is a progressive sclerosing,
inflammatory cholangiopathy of unknown aetiol-
ogy. Affecting between 1/5000–1/19,000 newborns,
this rare disease usually presents within the firstJournal of Hepatology 2017 vol. 66 j 6three months of life with conjugated hyperbilirubi-
naemia and cholestasis [40]. BA is classified anatom-
ically according to the level of the most proximal
biliary obstruction, the most common form being
type 3 (>90%) (Fig. 2) [40]. Twenty percent of
patients with BA demonstrate anatomical variants
including polysplenia and asplenia (also known as
biliary atresia splenic malformation syndrome
(BASM), gastrointestinal, venous and cardiac malfor-
mations [41]. Untreated, it progresses rapidly to bil-
iary cirrhosis and death within two years.
The Kasai procedure (portoenterostomy [KPE])
was first introduced by Morio Kasai in the 1950s
and has significantly improved outcomes for BA
[42]. Liver transplantation remains the only other
primary option for patients with BA and particularly
for those who fail a KPE [43]. A KPE does not cure
BA. 70% of patients post-Kasai with satisfactory bil-
iary drainage will develop progressive fibrosis/cir-
rhosis and portal hypertension with recurrent
cholangitis appearing to be one of the driving factors
and are all indications for transplantation respec-
tively [40]. BA is the most common indication for a
liver transplant at a paediatric liver transplant cen-
tre and has good outcomes which are comparable
to the entire cohort [44–46]. Common histological
findings include established cirrhosis with a central
hypertrophic area and relative atrophy of the
periphery of the liver [47]. In the hypertrophied area
of the liver, the liver architecture can be near normal
with bile ducts whereas the atrophic area usually
shows severe fibrosis and only a few bile ducts
remain [48]. Data is now available on long-term
follow-up in BA patients post-KPE [49–54] (Table 3)
ranging from 23–46% at 20 years [49,50,52]. Individ-
uals surviving into adulthood with their native liver
appear to have appropriate cognitive development
with one study reporting that 88% were employed
or attending higher education [53].31–644
I IIa IIb III
Fig. 2. Classification of biliary atresia. Type I, bile ducts are patent from the porta hepatis to the common bile duct and cystic duct; Type IIa, bile ducts are patent to the
common hepatic duct; Type IIb, the cystic, common duct are obliterated; Type III, obstruction from the extrahepatic bile ducts to the porta hepatitis (>90% cases).
Table 3. Long-term outcomes in patients with biliary atresia
post-Kasai portoenterostomy.
Author N Transplant free
survival at
20 years (%)
Study period
Lykavieris et al. 271 23 1968–1983
Chardot et al. 403 30 1986–2009
Shinkai et al. 28 44 1970–1986
De Vries et al. 104 43 1977–1988
Nio et al. 80 49 1970–1986
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- Management of portal hypertension. Clinical,
radiological and endoscopic evidence of portal
hypertension is evident in over two-thirds of
patients with 30% suffering a gastrointestinal
bleed [49]. Patients with known oesophageal
varices should undergo a yearly gastroscopy.
Management of the complications of portal
hypertension and its sequelae should therefore
follow accepted international guidelines [55].
- Management of cholangitis. Cholangitis is
commonly seen early after the Kasai surgery.
The majority of the patients surviving into
adulthood without a transplant do not develop
cholangitis and are not on any antibiotic pro-
phylaxis [56]. Cholangitis, if it occurs, should
be treated appropriately with intravenous or
oral antibiotics depending on the clinical and
biochemical severity at presentation. The
patency of the Roux loop should be investigated
with either cholescintigraphy and hepatobiliary
scintigraphy or enteroscopy.
- Timing of liver transplantation. Data suggests
that up to two-thirds of patients with BA post
KPE surviving into adulthood will develop hep-
atic complications [57]. BA post KPE appears to
be the leading indication for liver transplanta-
tion for patients in transition services [28]. Tim-
ing of liver transplantation and acceptance onto
adult waiting lists can be difficult. Due to pre-
served synthetic liver function, patients with
BA may have low MELD scores and therefore
may not fulfil minimal listing criteria. We rec-Journalommend referral to a liver transplant centre fol-
lowing the first episode of hepatic
decompensation or increase in the conjugated
bilirubin fraction.
- Hepatocellular carcinoma (HCC) risk. The
development of HCC appears to be rare in chil-
dren and optimal surveillance strategies in young
adults remains undefined [58]. A 6 monthly
ultrasound scan is recommended in addition to
measurement of serum alpha-fetoprotein levels.
Genetic cholestatic disorders
Progressive familial intrahepatic cholestasis (PFIC)
comprises a heterogenous group of autosomal reces-
sive liver disorders presenting in infancy or early
childhood [59,60]. However it can also present in
adulthood with episodes of cholestasis induced by
medications such as the oral contraceptive pill
(OCP), antibiotics or pregnancy. PFIC can be divided
into types -1,-2 and -3 according to the genetic
defects in the canalicular transporters (Fig. 3).
Approximately 10–15% of cases of cholestasis in
children are due to PFIC [59]. The diagnosis can be
made by genetic testing which is readily available.
PFIC1, also known as Byler’s disease is caused by
a mutation in the ATP8B1 gene on chromosome 18
(18q21-22). ATP8B1 encodes FIC1 (familial intrahep-
atic cholestasis 1) protein and is located on the
canalicular membrane of hepatocytes. It plays an
integral role in phospholipid translocation. Proposed
mechanisms for cholestasis include reduced bile salt
secretion due to farnesoid X receptor (FXR) down-
regulation and overloading of bile acids in hepato-
cytes due to bile salt export pump (BSEP)
downregulation and increased bile acid synthesis
within hepatocytes [61,62]. High expression of the
ATP8B1 gene is also noted in the cholangiocytes,
small bowel, kidney and pancreas and may account
for the symptoms of diarrhoea and pancreatic insuf-
ficiency in PFIC1 patients. Other associated clinical
features include short stature, severe pruritus and
deafness. Laboratory tests classically demonstrate a
normal or low gamma-glutamyl transferase (GGT),of Hepatology 2017 vol. 66 j 631–644 635
Tight junction
Bile acids
Drugs
Aminophospholipids
Phosphatidylcholine
Sitosterol 
Cholesterol
Conjugated bilirubin 
Glutathione
Bile 
canaliculus
PFIC2 
• Normal GGT
Hepatocyte
PFIC3 
• High GGTPARACELLULAR 
PATHWAY
FIC1 
(ATP8B1)
MRP2 
(ABCC2)
MDR3 
(ABCB4)
ABCG5/8
BSEP 
(ABCB11)
MDR1 
(ABCB1)
BloodPFIC1 
• Normal GGT
Fig. 3. Hepatobiliary transporters and their role on PFIC. Red dotted arrows demonstrate the phenotype expressed when a mutation occurs in the targeted transporter
gene. PFIC1, progressive familial intrahepatic cholestasis type 1; PFIC2, progressive familial intrahepatic cholestasis type 2; PFIC3, progressive familial intrahepatic
cholestasis type 3; MDR1/3, multi-drug resistance protein 1/3 (ABCB1/4 gene); GGT, gamma-glutamyl transferase; FIC1, familial intrahepatic cholestasis 1 (ATP8B1 gene);
BSEP, bile salt export pump (ABCB11 gene); MRP2, multidrug resistance associated protein 2. Modified from Joshi et al. [37].
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636mild elevation in transaminases and high bile acid
levels. Histological features include bland, canalicu-
lar cholestasis with absent centrilobular GGT
immunostaining, and portal and centrilobular
fibrosis (see Fig. 4C).
PFIC2 (also known as BSEP deficiency) is caused
by mutations in the ABCB11 gene which encodes
for the ATP-dependent canalicular BSEP located on
chromosome 2 (2q24) [63]. Defects result in
decreased bile salt excretion and subsequent accu-
mulation within hepatocytes and hepatocellular
damage. Patients with PFIC2 commonly present in
the neonatal period with severe pruritus, normal or
low GGT and grossly elevated raised transaminases
and serum bile acids. In both PFIC1 and PFIC2, the
normal or low serumGGT is due to failure of bile acid
excretion at the canicular level. Extrahepatic symp-
toms are uncommon. Histological features include
canalicular cholestasis, inflammation, portal fibrosis
and giant cell transformation. Inmost cases, absence
of canalicular BSEP expression can be demonstrated
with immunohistochemistry (see Fig. 4D). Low GGT
PFIC can also be associated with tight junction pro-
tein 2 (TJP2) deficiency, the defect resulting in dis-
ruption of the tight junction [64–66].
PFIC3 is associated with a high GGT and is
caused by defects in the adenosine triphosphate-
binding cassette subfamily B, member 4 (ABCB4)
gene which encodes the multidrug resistance class
3 (MDR3) protein. The MDR3 protein is located on
chromosome 7 (7q21) and is involved in phospho-Journal of Hepatology 2017 vol. 66 j 6lipid translocation. PFIC3 is one manifestation of
MDR3 deficiency. Others manifestations include
cholelithiasis, intrahepatic cholestasis of pregnancy,
drug-induced cholestasis and a cholangiopathy/bil-
iary cirrhosis in adults. MDR3 deficiency results in
biliary epithelial and canalicular damage due to
hydrophobic bile salt accumulation. Clinical features
of PFIC3 include pruritus and an absence of extra-
hepatic symptoms. Histological changes include bile
duct damage, ductular proliferation and biliary
fibrosis (see Fig. 4E).
Key management issues:
- The OCP is contraindicated in patients with PFIC
[39]. Female patients should be counselled
regarding the development of cholestasis during
pregnancy.
- Genetic cholestasis testing. Phenotypes that
should be tested by next generation sequencing
include: BSEP deficiency, FIC1 deficiency, TJP2
deficiency, MDR3 deficiency, FXR deficiency,
citrin deficiency, transaldolase deficiency, Alag-
ille syndrome.
- Ursodeoxycholic acid. Treatment for all forms of
PFIC involves the use of UDCA which can lead to
an improvement in liver function and in the
minority of cases resolution of pruritus [67,68].
- Pruritus. Medical management is first line i.e.,
UDCA, rifampicin, ondansetron [69]. Patients
may also benefit from nasobiliary drainage or31–644
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Fig. 4. Histological features from liver biopsies of various liver diseases. (A) A liver biopsy with severe steatosis from a 13 year old girl with non-alcoholic fatty liver
disease (NAFLD; H&E 100 magnification). There is mild portal fibrosis (see inset image of reticulin staining, 100 magnification), steatosis and minimal portal
inflammation. Portal based fibrosis and inflammation are more frequently seen in paediatric NAFLD than in adult NAFLD. Nuclear glycogenation of periportal hepatocytes is
a normal finding in paediatric liver biopsies. Peri-venular and peri-sinusoidal fibrosis (top left main image and reticulin stained inset) are less frequently seen in paediatric
NAFLD compared with NAFLD in adult patients. (B) A liver biopsy from a 55 year old man with NAFLD (H&E 200 magnification). There is severe steatosis with ballooning
of hepatocytes and nuclear glycogenation. The inset image shows peri-sinusoidal fibrosis (Picro Sirius Red staining, 200 magnification). (C) A liver biopsy from a 6 month
old child with ATP8B1 disease/PFIC1 (H&E 200 magnification). The hepatocytes are small and compact with minimal anisocytosis and minimal lobular activity. The black
arrows point to pale bile (‘‘Byler bile”) seen within dilated canaliculi. The inset image shows gamma glutamyl transpeptidase immunostaining (200magnification), which
marks canaliculi in periportal regions (white arrows) but is absent in centrilobular regions (inset image). (D) A liver biopsy from a ten week old baby with BSEP deficiency/
ABCB11 disease (H&E 200 magnification). There is giant cell hepatitis with canalicular cholestasis (black arrow) and moderate lobular activity. The inset image shows
absence of canalicular BSEP expression (bile salt export pump immunostaining, 200magnification). (E) A 5 year old child with ABCB4 disease/MDR3 deficiency (H&E 100
magnification). There is portal fibrosis with cholangiopathic features in the form of bile duct disarray and a ductular reaction (inset image, H&E 200 magnification).
Canalicular MDR3 immunostaining may be absent in a proportion of these patients. (F) A liver biopsy from a 6 month old infant with Alagille syndrome (H&E 100
magnification). There is portal fibrosis with fine fibrous septae radiating away from portal areas. Bile ducts are absent and there is no ductular reaction. The inset image
shows CK7 immunostaining (cytokeratin 7, 100magnification). The arrow points to the portal tract seen in the main image, in which bile ducts are not identified. There is
aberrant expression of CK7 in hepatocytes, compatible with chronic cholestasis.
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JOURNAL OF HEPATOLOGYsurgical biliary diversion although limited effi-
cacy is reported in patients with established
chronic liver disease [70,71]. Bile salt seques-
trants can be used in patients with diarrhoea.
The role of FXR agonists remains undefined at
present. Liver transplantation remains an option
in patients with progressive liver disease but
recurrence post-transplantation is possible
especially in patients with PFIC3 and BSEP
deficiency.
- Liver transplantation. Indicated in patients
with end-stage liver disease and intractable pru-
ritus and is regarded as curative in PFIC2. The
multi-system involvement however persists
post-liver transplantation in PFIC1. Specifically,
recurrence of steatosis and diarrhoea is seen
post liver transplantation and management can
be quite challenging [72] Hepatocyte therapy,
gene and chaperone therapy, potentiators orJournalspecific targeted pharmacotherapy for pruritus
and the gene defect are likely to become avail-
able in the future [73].
- HCC risk. A significantly increased risk of HCC is
evident in PFIC2 [74]. Standard HCC surveillance
is therefore recommended.
Alagille syndrome
Alagille syndrome is an autosomal dominant disor-
der which occurs secondary to mutations in the
JAG1 gene in the majority of cases (>95%), although
expression is variable [75,76]. The remaining cases
are associated with mutations in the NOTCH2 gene
[75]. Presentation is usually at birth or within early
life with cholestasis, ‘butterfly’ vertebral arch defect,
typical facial features comprising of deep and low
set eyes, and ‘triangular facies’, and is oftenof Hepatology 2017 vol. 66 j 631–644 637
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638associated with peripheral pulmonary artery hypo-
plasia or stenosis. Pruritus can be severe. Intrahep-
atic bile duct paucity is seen on histology though
early on, it may be masqueraded by evidence of bile
duct proliferation. Bile duct obliteration is progres-
sive resulting in variable fibrosis (see Fig. 4F). End-
stage liver disease occurs in approximately 20–30%
of cases [77,78]. Renal abnormalities (renal tubular
acidosis) can also occur.
Key management issues:
- Ursodeoxycholic acid. May help with symp-
toms and biochemical improvement.
- Liver transplantation. Data published suggest a
good clinical outcome following liver transplan-
tation but is dependent upon concurrent renal,
cardiac and respiratory dysfunction [71,79].
Alpha-1 antitrypsin deficiency
Alpha-1 antitrypsin (A1AT) is a serum glycoprotein
synthesized in the liver and in alveolar macro-
phages. Its primary function is as a neutrophil pro-
tease inhibitor. A1AT deficiency remains the most
common inherited (autosomal dominant) cause of
infantile liver disease [80].
More than 100 variant alleles of A1AT gene
(SERPINA1) have been identified but the majority
of patients with liver disease are homozygous for
the Z mutant allele referred to as ZZ or Pi⁄ZZ [81].
Reduced levels of A1AT are also associated with
the PiZNul and PiNulNul variants [82]. Normal
levels of A1AT are seen in individuals who carry
the most common allele (M). Hepatic injury is
caused by the polymerisation and accumulation of
the protein product of the Z gene in the endoplas-
mic reticulum of hepatocytes. Pi⁄ZZ homozygous
individuals are also at risk of developing pulmonary
emphysema which occurs due to insufficient avail-
ability of A1AT in the pulmonary system to inhibit
connective tissue breakdown.
Clinical presentation is variable ranging from
abnormal liver function tests to cirrhosis and HCC
[81,83]. The clinical penetrance is variable with
only 20% of patients with A1AT deficiency develop-
ing clinically significant liver disease. Presentation
can therefore be in young adults commonly with
abnormal liver function tests. The clinical presenta-
tion can be very similar to BA and therefore the
phenotype should be determined in all suspected
cases of BA. A1AT within hepatocytes stains posi-
tively with periodic acid-Schiff reagent but are only
detectable after 12 weeks of life.
Key management issues:
- Treatment for those presenting with cholestasis
is supportive with replacement of fat and water-
soluble vitamins. Asymptomatic patients shouldJournal of Hepatology 2017 vol. 66 j 6be reviewed on a 6–12 monthly basis. Alcohol
consumption should be minimized as well as
smoking and exposure to passive smoking. Base-
line lung function should be performed.
- Liver transplantation. Liver transplantation is
the only therapeutic option in patients with hep-
atic decompensation often characterised by syn-
thetic failure. Following liver transplantation,
A1AT levels should normalise assuming the
donor is Pi⁄MM and pulmonary disease should
not progress any further.
Other metabolic disorders
Other metabolic disorders include glycogen storage
diseases, lysosomal storage disorders and urea cycle
disorders. Table 4 summarises the clinical features
and available treatment options. Additionally,
patients who were transplanted for cryptogenic cir-
rhosis may warrant additional testing such as Next
Gen sequencing, exome sequencing based on clinical
symptoms which may not have been available at the
time of transplant.Diseases that occur in children/adolescents and
adults
Autoimmune hepatitis and autoimmune sclerosing
cholangitis
Autoimmune hepatitis (AIH) is a chronic, immune-
mediated liver disease characterised by high serum
transaminases, high immunoglobulin G (IgG) levels,
detectable autoantibodies and histologically by the
presence of interface hepatitis [84]. AIH is a rare
condition both in adults and children, with a
reported incidence of 0.4 and 3.0/100,000 children
[85,86].
Children vs. adults
Subtle differences are observed in paediatric
patients presenting with AIH. Nearly two-thirds of
patients in childhood have type 1 AIH (positive
anti-nuclear antibody [ANA] and/or anti-smooth
muscle antibody [SMA]) and tend to present at the
time of puberty often with features of cirrhosis on
biopsy [87]. Type 2 AIH (positive anti-liver kidney
microsomal type 1 antibody [LKM1] and/or anti-
liver cytosol type 1 antibody [anti-LC1]) affects
younger patients (median age 7 years). Higher
serum bilirubin levels and transaminases at presen-
tation are noted and patients have a higher propen-
sity to present with fulminant hepatic failure
[87,88]. Approximately 50% of children will be cir-
rhotic at presentation [87,89–91]. Type 1 AIH
(ANA/ASMA+) is the most common form in adults
and tends to present between the ages of 40–
50 years, although, it may present at any age level31–644
Table 4. Metabolic disorders in young adults.
Disorder Defect Clinical features
Glycogen storage
diseases
Type I – Glucose-6-phosphatase Hepatomegaly, lactic acidosis, ketotic hypoglycaemia,
hyperlipidaemia, hypertriglyceridaemia, neutropenia.
Treatment: uncooked cornstarch, allopurinol, GCSF.
Monitoring: Risk of development of hepatic adenoma.
Monitoring with USS and AFP is recommended.
Type III – Glycogen debrancher Ketosis, hypoglycaemia, hepatomegaly.
Treatment: uncooked starch.
Monitoring: Risk of development of hepatic adenoma.
Monitoring with USS and AFP is recommended.
Type IV – Glycogen branching Hepatomegaly.
Treatment: liver transplantation
Lysosomal
storage diseases
Fabry’s disease – X linked, deficiency or defect in lysosomal hydrolase
alpha-galactosidase
Accumulation of globotriasylceramide within lysosomes in
renal tubules, interstitial cells, cardiac muscle cells and
vascular smooth muscle cells.
Gaucher’s disease – autosomal recessive, mutation in
glucocerebrosidase gene (chromosome 1q21). Most common
lysosomal storage disease
Deficiency in glucoysl-ceramide-B-glucosidase in leucocytes,
hepatocytes and aminocytes. Three subtypes (Type I, II, III).
Type I does not have CNS involvement.
Treatment: replace deficient enzyme.
Urea cycle
disorders
N-acetyl glutamate synthetase deficiency Hyperammonaemia, autosomal recessive, seizures
Carbamyl phosphate synthetase I deficiency Hyperammonaemia, autosomal recessive, seizures
Ornithine transcarbamylase deficiency Hyperammonaemia, X linked inheritance, seizures
Argininosuccinate synthetase deficiency (Citrullinemia) Hyperammonaemia, autosomal recessive, seizures
Argininosuccinate lyase deficiency Hyperammonaemia, autosomal recessive, seizures
Arginase deficiency Autosomal recessive, seizures
Mitochondrial
disorders
Numerous clinical syndromes including:
Leber hereditary optic neuropathy, maternally inherited deafness and
diabetes, mitochondrial encephalomyopathy with lactic acidosis and
stroke like episodes (MELAS)
Isolated myopathy
Encephalomyopathy in infancy and childhood
External ophthalmoplegia
Multisystemic disease with myopathy
Lysosomal acid
lipase (LAL)
deficiency
Autosomal recessive.
Also known as cholesteryl ester storage disease (CESD)
Liver fibrosis and cirrhosis. Increased risk of strokes.
High cholesterol and triglycerides (high LDL and low HDL),
hepatomegaly
Treatment: none at present
USS, ultra sound scan; GCSF, granulocyte colony-stimulating factor; AFP, alpha-fetoprotein; CNS, central nervous system; LDL, low density lipoprotein; HDL, high density
lipoprotein.
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children and adults.
The most common presentation of AIH in child-
hood (approximately 40%) is usually non-specific
and may be similar in phenotype to an acute viral
hepatitis i.e., malaise, nausea, vomiting, anorexia,
abdominal pain followed by jaundice, dark urine
and pale stools [87]. An uncommon presentation
in less than 10% of patients is signs and symptoms
of portal hypertension. The remaining patients
often present insidiously, with more subtle symp-
toms of weight loss, anorexia, malaise occurring
over many years. The presentation in adults is sim-
ilar and varies from mild biochemical abnormali-
ties to sub-acute liver failure [93]. Differences in
autoimmune liver disease between children and
adults is summarised in Table 5. Patients diagnosed
with AIH under the age of 18 years have an
increased risk for disease relapse, are more likely
to need liver transplantation and have a reduced
life expectancy compared to adults [94,95].
Autoimmune sclerosing cholangitis (ASC) is a
unique form of sclerosing cholangitis with gross
autoimmune features (positive ANA and/or SMA
antibodies, high titres of IgG and interface hepatitis)Journaland a cholangiopathy on imaging, which has been
described in children [89]. Liver biochemistry may
not be indicative of cholestasis. The seminal publica-
tion on ASC highlighted a similar prevalence as type
1 AIH with both sexes being affected equally [89].
Associated autoimmune diseases, in particular,
inflammatory bowel disease (IBD) is common in
patients with ASC [87,89]. A strong association with
HLADRB1⁄1301 is described in patientswithASC [96].
The International Autoimmune Hepatitis Group
(IAIHG) have developed diagnostic criteria for AIH
in adults which has been widely used in children
[97,98]. Recently, EASL Clinical Practice Guidelines
recommend the use of the simplified IAIHG criteria
to aid diagnosis, whilst reserving the modified crite-
ria for difficult to diagnose cases [96].
Key management issues:
The treatment goals are to normalise serum
transaminases, IgG levels and achieve negative or
low titres of autoantibodies (61:20 ANA or SMA or
61:10 anti-LKM-1) resulting in an improvement in
histological inflammation. Equally, additional goals
should be to maintain remission and prevent the
progression of the disease to cirrhosis.of Hepatology 2017 vol. 66 j 631–644 639
Table 5. Autoimmune liver disease – children and adults.
Children Adults
Sub-type Type 1–66% Type 1 >Type 2
Sex Female >male (3:1)
(1:1 – ASC)
Female >male (3:1)
Age of onset* Type 1–11 years
Type 2–7 years
ASC – 12 years
40–50 years
Clinical presentation Acute hepatitis >insidious >acute
liver failure
Acute hepatitis >insidious >chronic liver disease
>acute liver failure
Concurrent autoimmune
disease
Approximately 20%
More common in ASC
Common
Cirrhosis at presentation (%) 50 33
Relapse rate (%) 44 40
Liver transplantation rate (%) 10
25 in ASC
10
Recurrence post-liver
transplantation (%)
0 in Type 1 and Type 2
66 in ASC
12–42
* Median age. ASC, autoimmune sclerosing cholangitis.
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640- Treatment. The mainstay of treatment in both
adults and children is the use of prednisolone.
In children 2 mg/kg/day (maximum 60 mg/day)
is started and then tapered over a period of 6–
8 weeks to a maintenance dose of between
2.5–5 mg/day, whereas, proportionally lower
doses (0.5–1.0 mg/kg/day) are used in adults
[96]. We recommend azathioprine as a steroid
sparing agent (starting dose 0.5 kg/day) in indi-
viduals whose transaminases stop decreasing
on prednisolone therapy. 6-mercaptopurine
(1.5 mg/kg/day) can also be used. Thiopurine
methyltransferase (TPMT) activity measurement
is recommended prior to initiation of azathio-
prine. The introduction of azathioprine should
be delayed in cases with elevated bilirubin
>100 lmol/L. Thioguanine metabolites can be
measured to ensure individuals are on appropri-
ate therapeutic doses, adherent and not devel-
oping hepatotoxicity [99]. Budesonide (9 mg
daily) may be an alternative in patients who
are unable to tolerate prednisolone but has lim-
ited efficacy in individuals with cirrhosis [100].
- Treatment regimens for ASC are similar to AIH
but the addition of UDCA (15–20 mg/kg/day) is
also recommended.
- Refractory disease. Patients who fail azathio-
prine therapy or with refractory relapsing dis-
ease should be considered for treatment with
mycophenolate mofetil, which can lead to
remission in approximately 10% of children
[101]. Calcineurin inhibitors (cyclosporine and
tacrolimus) have also been used with good effi-
cacy, but the data is limited to small numbers
and limited long-term follow-up [102–105].
- Disease relapse. Relapse is common, affecting
approximately 40% of children and 50% of adults
and is frequently associated with non-adherence
[95,106]. Relapse in disease is confirmed by an
increase in autoantibody titres, rise in globulin
fraction, serum transaminases and exclusion of
non-adherence. Relapse is typically treated withJournal of Hepatology 2017 vol. 66 j 6the reintroduction of prednisolone or increase in
dose and consideration of alternative therapies
[107].
- Treatment duration. The optimal duration of
therapy remains unknown, although for many
children and adolescents, lifelong therapy is
needed. Patients often require repeat liver biop-
sies to determine ongoing evidence of inflamma-
tion and fibrosis progression. We recommend
treatment withdrawal only after 3 years with
the provision of no active inflammation or cirrho-
sis on liver biopsy, normal liver biochemistry and
negative autoantibodies in the preceding 2 years.
Studies in both children and adults have reported
sustained immunosuppression free rates of up to
40% at 5 years [108,109], although data in adult
patients from Europe suggests lower rates of sus-
tained remission [110]. Withdrawal of treatment
is not recommended during puberty, pregnancy,
concurrent IBD or during the transition period.
Patients should be counselled to explain that
relapse is common after withdrawal of treatment
affecting approximately 70% of patients
[109,111,112].
- Long-term management and liver transplanta-
tion. Adult and children with AIH should have
bone density assessment performed every 3–
5 years [96]. In addition, patients should also be
screened and vaccinated against hepatitis A and
hepatitis B viruses. Patients receiving azathio-
prine or 6-mercaptopurine should be educated
on the dangers of excessive sun exposure. Overall
the prognosis of AIH in children who respond to
treatment is good. However, approximately 10%
of patients with AIH and 20% of patients with
ASC will require liver transplantation [87,113].
Non-alcohol related fatty liver disease
Data from the UK and the USA estimates the preva-
lence rate of obesity to be 9–17% in children and31–644
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young adults [114,115]. In parallel to this rising
epidemic of obesity, non-alcoholic fatty liver dis-
ease (NAFLD) is now the most common cause of
chronic liver disease in both children and adults.
Male children appear to be more affected than their
female counterparts [115,116]. The histological
findings in children and adults are different and
are summarised in Fig. 4A and B. The long-term
prognosis of paediatric NAFLD is unclear, but pro-
gression to severe liver disease does occur. Impor-
tant differential diagnoses include Wilson’s
disease, urea cycle defects, fatty acid oxidation
defects, lysosomal acid lipase deficiency and mito-
chondrial cytopathies.
Insulin resistance appears to be the final com-
mon pathway of a number of different mechanisms
including increased pro-inflammatory cytokine pro-
duction and reduced adiponectin [117,118]. Leptin
resistance leads to free fatty acid accumulation in
vacuoles which results in hepatocyte injury through
oxidative stress, endoplasmic stress and mitochon-
drial dysfunction [119,120]. Hepatocyte death sub-
sequently results in fibrogenesis through hepatic
stellate cell activation [121]. Other pathophysiolog-
ical mechanisms implicated include single nucleo-
tide polymorphisms in patatin-like phospholipase
domain-containing protein (PNPLA3), increased
consumption of trans fats and fructose, intestinal
dysbiosis and bacterial translocation, and an
increase in male sex hormones [122–127].
Key management issues:
- Treatment. There are limited treatment options
for the treatment of NAFLD in children and
young adults. Management strategies should tar-
get any modifiable risk factors for the metabolic
syndrome. Dietary modifications including
improving the quality of school dinners and
increased exercise are critical interventions in
reducing patient body weight. A study that used
an improvement in liver histology as its primary
endpoint demonstrated that two years of
increased physical activity and lifestyle interven-
tion with an individual calorie diet resulted in a
significant improvement in the severity of
steatosis, inflammation and hepatocyte balloon-
ing and the NAFLD activity score [128]. The study
also reported an improvement in liver enzymes,
insulin resistance and serum lipid levels [128].
The TONIC study, a double-blind placebo con-
trolled trial compared vitamin E or metformin
for 96 weeks [129]. The primary outcomes was
a sustained reduction in alanine transferase
whilst secondary outcomes were improvement
in histological features and resolution of non-
alcoholic steatohepatitis (NASH). Although the
primary outcome was not achieved, vitamin E
was associated with resolution of NASH and an
improvement in hepatocyte ballooning suggest-
ing the need for future studies [129].Journal- Newer therapies. Although not used specifically
in children or young adults, the FLINT study
assessed the efficacy of obeticholic acid (FXR ago-
nist) in adults with NASH for 72 weeks [130].
Obeticholic acid resulted in an improvement in
histology compared to placebo (45% vs. 21%,
p = 0.0002) but nearly one-third of patients
developed pruritus and increased serum low-
density lipoprotein levels. More data is therefore
required on the use of obeticholic acid in patients
with NAFLD.
- Bariatric surgery. ESPGHAN (European society
for paediatric gastroenterology, hepatology and
nutrition) have recently published a position
statement on the role of bariatric surgery in
young adults [131]. The benefits of bariatric
surgery are plentiful and include the obvious;
reduction in weight and BMI, to the more sub-
tle improvement in systemic inflammation, glu-
cose tolerance and dyslipidaemia. ESPGHAN
conclude that bariatric surgery should be con-
sidered in patients without cirrhosis and with
the support of a specialized multi-disciplinary
team [131].
Wilson’s disease
Wilson’s disease is an autosomal recessive disorder
which causes impaired cellular transport of copper
resulting in accumulation in the liver, brain and cor-
nea. The genetic mutation is in the ATP7B gene
located on chromosome 13 [132]. More than 500
different mutations have been described in the Wil-
son gene but the clinical significance of every muta-
tion remains unclear.
Key management issues:
- A comprehensive history should also include
review of neurocognitive development and
schooling/academic performance and progress.
- EASL guidelines published in 2012 provide fur-
ther details on diagnosis and the interpretation
of the different investigations [133]. Screening
of family members and offspring is
recommended.
- Untreated, Wilson’s disease is fatal usually from
liver disease. Treatment is therefore lifelong. D-
penicillamine (750–1500 mg/day BD or TDS) pro-
motes the urinary excretion of copper but also
induces metallothioneins, which are endogenous
chelators of metals. It should be taken 1–2 h
before meals to inhibit the dietary absorption of
copper. Pyridoxine supplements are required. D-
penicillamine is poorly tolerated in almost one-
third of patients and may worsen neurological
symptoms. Alternatives include trientine (copper
chelator and promoter of urinary copper excre-
tion) which is usually better tolerated than D-
penicillamine and zinc (reduces uptake of copperof Hepatology 2017 vol. 66 j 631–644 641
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